【Asset for Licensing】Orally bioavailable selective PI3Kα small-molecule inhibitor

Asset: Orally bioavailable selective PI3Kα small-molecule inhibitor
Development Stage: IND enabling stage
Indication: Breast Cancer, Cervical Cancer, Ovarian Cancer
Key Asset Highlights:
（1）Exhibits high selectivity and potent inhibitory activity against PI3Kα, a core driver of abnormal PI3K/AKT/mTOR signaling that dominates the proliferation and progression of multiple gynecological and breast malignancies.
（2）Effectively blocks aberrant PI3Kα-mediated signaling cascade, significantly suppressing tumor cell proliferation, invasion and metastasis in PI3Kα-mutant breast, cervical and ovarian cancer preclinical models.
（3）Demonstrates prominent differentiated advantages over pan-PI3K inhibitors, delivering potent anti-tumor efficacy while minimizing off-target-related toxicities to achieve an improved therapeutic index.
（4）Shows robust anti-tumor activity against recurrent and drug-resistant gynecologic and breast tumors, providing a novel targeted therapeutic strategy for patients with unmet clinical treatment needs.
（5）Possesses favorable oral pharmacokinetic properties and a broad safety window, supporting convenient oral administration and long-term clinical intervention for multiple malignant tumors.
（6）Protected by a comprehensive and robust global intellectual property portfolio, securing exclusive and stable development and commercialization rights for PI3Kα-targeted tumor therapy.

If you are a Search & Evaluation professional working at an MNC, biopharma, biotech or VC, and are interested in this opportunity, please feel free to contact the DrugTimes BD Team.

Email: BD@drugtimes.cn

Thank you very much!

【Disclaimer】All information presented above and on this website is provided for informational purposes only. We make no guarantee as to its accuracy, completeness or timeliness. Readers shall exercise caution when referencing the content.